Future research should explore whether SQSTM1 mutations can act as primary drivers or cofactors in the pathogenesis of neuromuscular diseases. Further studies are needed to determine whether SQSTM1 mutations could serve as pathogenic drivers or modifiers in seronegative neuromuscular disorders. This evidence concerns the gene SQSTM1 and neuromuscular disease.